Last reviewed · How we verify
Topical corticosteroids
Topical corticosteroids suppress local immune and inflammatory responses by binding to glucocorticoid receptors in skin cells.
Topical corticosteroids suppress local immune and inflammatory responses by binding to glucocorticoid receptors in skin cells. Used for Inflammatory skin conditions including eczema, psoriasis, and dermatitis, Pruritus and other allergic skin reactions, Lichen planus and other inflammatory dermatoses.
At a glance
| Generic name | Topical corticosteroids |
|---|---|
| Sponsor | Sanofi |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
These agents penetrate the skin and bind intracellular glucocorticoid receptors, leading to suppression of pro-inflammatory cytokine production, reduced immune cell infiltration, and decreased vasodilation. This results in reduced erythema, pruritus, and other inflammatory manifestations of dermatological conditions. Potency varies by formulation and molecular structure.
Approved indications
- Inflammatory skin conditions including eczema, psoriasis, and dermatitis
- Pruritus and other allergic skin reactions
- Lichen planus and other inflammatory dermatoses
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Systemic absorption (with prolonged use on large areas)
Key clinical trials
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants (PHASE2)
- A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis (PHASE3)
- Dual-light Antibacterial Photodynamic Therapy as an Adjunctive Treatment to Corticosteroid Treatment in OLP (NA)
- Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials (PHASE2, PHASE3)
- Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
- Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical corticosteroids CI brief — competitive landscape report
- Topical corticosteroids updates RSS · CI watch RSS
- Sanofi portfolio CI